Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Radioimmunotherapy × Clear all
NCT00002554 2010-03-30

Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse

Fred Hutchinson Cancer Center

Phase 2 Completed
30 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00177554 2008-05-29

Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

University of Pittsburgh

Phase 2 Completed
60 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡